ArticleCureus2026
Malignant Catatonia From Paliperidone Withdrawal With Successful Pharmacological Treatment: A Diagnostic and Therapeutic Challenge.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catatonia is a neuropsychiatric syndrome of psychomotor disturbances occurring in various psychiatric and medical conditions, as well as from adverse effects of antipsychotics. Malignant catatonia is a severe, life-threatening subtype characterized by autonomic instability along with typical catatonia features. It requires immediate treatment with electroconvulsive therapy (ECT) in critical care settings. While oral antipsychotics are well-recognized causes of withdrawal catatonia, cases related to long-acting injectable antipsychotic drugs causing withdrawal catatonia occur less commonly. We present a case of a 43-year-old man with schizophrenia, major depressive disorder, and generalized anxiety disorder who had been on paliperidone. The patient presented to the hospital after missing a dose of paliperidone with symptoms consistent with catatonia. His condition rapidly deteriorated, leading to malignant catatonia. The ECT plan was deferred due to non-availability at the facility and the family's wishes. The patient was treated with high-dose benzodiazepines, which successfully improved his symptoms. He had a prolonged hospital stay due to slow recovery and was discharged on a long taper of benzodiazepines. Paliperidone was resumed as an outpatient because of concerns about rebound catatonia following immediate resumption during hospitalization. This case highlights several atypical features related to catatonia and long-acting injectable antipsychotic medications. It also emphasizes the importance of potential adverse effects from medication nonadherence, especially with long-acting injectable antipsychotics, which can pose diagnostic challenges. Early recognition of malignant hyperthermia, aggressive benzodiazepine dose escalation, and ECT remain cornerstones of successful management. The case further highlights therapeutic challenges in psychiatric emergencies due to patient and system factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.